AIM
MGNX icon

Acrospire Investment Management’s MacroGenics MGNX Stock Holding History

Acrospire Investment Management’s Portfolio MGNX Stock Details MGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-1,700
Closed -$35K – 2379
2016
Q4 		$35K Buy
+1,700
New +$42.8K 0.01% 1572

Other funds holding MGNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BRC
Blue Ridge Capital New York $215M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

Acrospire Investment Management's MGNX Position: Q1 2017 in Review

Acrospire Investment Management sold out of MacroGenics (MGNX) in Q1 2017, closing a stake of 1,700 shares — an estimated $35K sold.

Acrospire Investment Management first reported a position in MGNX in Q4 2016 and held it in 1 quarter. The position peaked at $35K in Q4 2016. 111 funds tracked by Wall St. Rank hold MGNX as of Q1 2017.

  • Acrospire Investment Management reported no remaining MacroGenics position as of Q1 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 1,700 MacroGenics shares in Q1 2017, an estimated $35K.
  • Acrospire Investment Management first reported a position in MacroGenics in Q4 2016 and held it in 1 quarter.
  • Acrospire Investment Management's MacroGenics position peaked at $35K in Q4 2016.
  • 111 funds tracked by Wall St. Rank held MacroGenics as of Q1 2017.

Based on Acrospire Investment Management's 13F filing for Q1 2017, filed 4 May 2017.